The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Multiple Myeloma
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
-
Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona, United States, 85054
City of Hope, Duarte, California, United States, 91010
University of California San Francisco, San Francisco, California, United States, 94143
Stanford University Medical Center, Stanford, California, United States, 94305-5623
Emory University, Atlanta, Georgia, United States, 30322
Northwestern University, Chicago, Illinois, United States, 60611
University of Chicago, Chicago, Illinois, United States, 60637
Indiana University, Indianapolis, Indiana, United States, 46202
Kansas University Medical Center, Westwood, Kansas, United States, 66205
Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02115
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Janssen Research & Development, LLC,
Janssen Research & Development, LLC Clinical Trial, STUDY_DIRECTOR, Janssen Research & Development, LLC
2037-07-29